title: [Absolute risk for fracture and WHO guideline. Treatment of patients with secondary osteoporosis].
abstract: There has been accumulating evidence that various diseases and drugs cause increased risk of fracture. Although the treatment of primary diseases and discontinuation of drugs are the first and ideal option for the cure of secondary osteoporosis, medical intervention for osteoporosis is often necessary. The mechanisms, which induce bone fragility, are supposed to be different, depending on diseases and drugs. Guidelines for the evaluation and treatment of secondary osteoporosis have not been established except glucocorticoid-induced osteoporosis. In patients with osteoporosis caused by primary hyperparathyroidism, hyperthyroidism, diabetes mellitus as well as hormone deprivation therapy, bisphosphonate is effective in increasing bone mineral density but no data have been available about the fracture risk. Guidelines on the management and treatment of each secondary osteoporosis are desirable.
authors.affiliation: Shimane University Faculty of Medicine, Internal medicine 1.
authors.forename: Mika
authors.initials: M
authors.lastname: Yamauchi
mesh_terms: D047072:Aromatase Inhibitors / Q000009:adverse effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002762:Cholecalciferol / Q000627:therapeutic use*; D048909:Diabetes Complications; D004164:Diphosphonates / Q000627:therapeutic use*; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D006961:Hyperparathyroidism / Q000150:complications / Q000601:surgery; D006980:Hyperthyroidism / Q000150:complications; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology*; D016105:Parathyroidectomy; D012306:Risk; D024482:Vitamin K 2 / Q000627:therapeutic use*
chemical_list: D047072:Aromatase Inhibitors; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005938:Glucocorticoids; D024482:Vitamin K 2; D002762:Cholecalciferol